

RECORDATI: PUBLIC DISCLOSURE

Milan, 8 March 2017 – Please be informed that the Directors' Reports relating to the item 4 (Remuneration policies) and item 5 (Purchase and utilization of treasury stock) of the agenda of the Ordinary Shareholders' Meeting, and item 1 (authorization for capital increases ex articles 2420-ter and 2443 Italian Civil Code) of the agenda of the Extraordinary Shareholders' Meeting called for April 11th 2017, single call, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "1info" storage mechanism (www.1info.it).

Furthermore, please be informed that the 2016 Report on Remuneration approved by the Board of Directors on 1st March 2017 is also available to the public, as of today, by the means indicated above (with reference to the Company's website: Section Corporate Governance, Remuneration).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America and in some Latin American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832